[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"London Health Sciences Centre\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":76},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100557642","therapeutic-normothermia-in-tbi-100557642",false,"NCT06540768","Therapeutic Normothermia in TBI","Therapeutic Normothermia in the Treatment of Traumatic Brain Injury Trial: Feasibility Trial","MAMBA-FT","Inclusion Criteria:\n\n* Adult patients (\\>= 18 years of age) who present through the LHSC trauma service and have sustained a TBI.\n* A Glasgow Coma Scale (GCS) of 5-12, inclusive, prior to intubation.\n\nExclusion Criteria:\n\n* GCS at time of presentation of 4 or less or 13 or more.\n* Patients not expected to survive 48 hours.\n* \\>24 hours from injury at time of enrollment.","ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","This feasibility trial is the first step in testing the hypothesis that maintenance of normal body temperature, called therapeutic normothermia (TN), for 72 continuous hours in traumatic brain injury (TBI) patients can improve cognitive function. The trial aims to answer the following questions:\n\n1. Is it feasible to conduct this study? Conducting the trial includes the ability to identify and enroll appropriate participants, implement TN, and collect the required data.\n2. Can the Creyos Health platform cognitive assessment tool be used to assess and quantify cognitive outcomes in TBI patients?\n\nResearchers will address the aforementioned questions by looking at the following factors:\n\n1. Identification and enrollment rates of appropriate patients\n2. Implementation of the intervention and appropriate data collection while admitted\n3. Accurate follow up and continued data collection post-discharge\n4. Accessibility and ease of use of the Creyos Health platform cognitive assessment tool\n\nParticipants will undergo the following procedure:\n\n1. Admission to the Critical Care Trauma Centre through the trauma service\n2. Allocation to the intervention or no intervention group\n3. Implementation of the intervention or of usual care for a continuous 72 hours\n4. Completion of the Creyos Health platform cognitive assessment tool at 3 and 6 months post-discharge from the Critical Care Trauma Centre",[27],"Traumatic Brain Injury",[29,30,31,32,33],"TBI","therapeutic normothermia","targeted temperature management","cognitive outcomes","traumatic brain injury","NOT_YET_RECRUITING","2024-12-11",{"date":37,"type":38},"2024-12-16","ACTUAL",{"date":40,"type":21},"2025-01",{"date":42,"type":21},"2025-12",{"name":44,"class":45},"London Health Sciences Centre","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":64,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100358421","abdominal-regional-perfusion-in-donation-after-cardiac-death-for-multi-organ-transplantation-100358421","NCT03946852","Abdominal Regional Perfusion in Donation After Cardiac Death for Multi-Organ Transplantation","Recipient Criteria:\n\nInclusion Criteria- Indications for Liver transplant include decompensated Cirrhosis of any etiology Model for End-Stage Liver Disease (MELD) score \\> 15 with no contraindications to liver transplant as per conventional clinical practice.\n\nAcute or fulminant liver failure Advanced malignancy such as HCC, cholangiocarcinoma, neuroendocrine tumor, or other cancer meeting criteria for listing and exception points as per current clinical guidelines.\n\nExclusion Criteria-\n\n* Inadequate social support for liver transplant\n* Non-compliance with alcohol or narcotic cessation\n* Evidence of uncontrolled infection\n* Other untreated malignancy aside from those listed above\n* Physiologic evidence of frailty based on timed up and go, grip strength, 6 minute walk test, and cognitive testing.\n\nDonor Criteria:\n\nDCD donors offered via TGLN will be considered for assessment via abdominal regional perfusion based on the following parameters. These are in keeping with current criteria for abdominal organ donors.\n\n* Age: Up to 70 years of age within the initial evaluation period, with plans to expand to 75 y\u002Fo if initial results are favourable.\n* BMI: Donor BMI must be less than 30 for consideration\n* DCD donation criteria: Conventional criteria for DCD donation must be met, including no expectation for viable recovery, without meeting criteria for brain death, and expressed desire by family for organ donation.\n* Comorbidity: In the opinion of the on-call transplant surgeon, there should not be excessive comorbidity to exclude organ donation\n* Active infection: There should be no untreated infection.\n* Malignancy: Donors should have no evidence of active malignancy, or in the case of a treated malignancy there should be sufficient interval to rule out recurrence. In select cases, donors with tumors known to be indolent may be considered on a case by case basis.\n\nLiver transplant release Criteria:\n\nOne of the major advantages of ARP beyond reconditioning the organ prior to cold storage and transplant, is an opportunity to assess graft function in-situ prior to transplant. The existing literature supports the use of multiple readily available laboratory tests to evaluate graft function prior to transplant. Donor labs will be drawn every 30 minutes from the perfusion circuit to evaluate organ function.\n\n* Transaminase: Initial transaminases (AST and ALT) drawn at the start of perfusion must be less than 4 times the upper limit of normal and stay below this threshold throughout the reperfusion process to be considered for use with an absolute cut-off of 500\n* Lactate: Grafts will only be used if lactate levels do not rise during perfusion, ideal organs will have a decrease in serum lactate levels by 1.11 mmol\u002FL per hour\n* Macroscopic appearance: On clinical evaluation, there should be no evidence of fibrosis or cirrhosis and organs should not have a macroscopically steatotic appearance.","75 Years",{"count":54,"type":21},20,[24],"The main purpose of this study is to increase the pool of organs available for donation by performing ARP to recondition donation after cardiac death (DCD) organs prior to transplantation. We will compare the outcomes of our ARP DCD liver transplants with historical data to determine the efficacy of this treatment compared to transplantation with standard DCD and donation after brain death (DBD) organs. We will also analyze biological samples from donors and recipients and compare them with outcome data in an effort to determine if any biological markers are able to predict the quality\u002Fsuccess of the grafts.",[58,59,60,61,62,63],"Liver Transplant; Complications","Ischemia Reperfusion Injury","Cirrhosis","Liver Cancer","Liver Metastases","End Stage Liver Disease",[65,66,67,59],"abdominal regional perfusion","Donation after Cardiac Death","Liver Transplantation","2019-05-09",{"date":70,"type":38},"2019-05-13",{"date":72,"type":21},"2019-06",{"date":74,"type":21},"2026-06",{"name":44,"class":45},""]